Printer Friendly
Printed from http://www.researchandmarkets.com/reports/2167189
House Dust Mite Allergy - Pipeline Review, H1 2012
Description:
House Dust Mite Allergy – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H1 2012', provides an overview of the House Dust Mite Allergy therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. 'House Dust Mite Allergy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for House Dust Mite Allergy.
- A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of House Dust Mite Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
House Dust Mite Allergy Therapeutic Products under Development, Key Players in House Dust Mite Allergy Therapeutics, House Dust Mite Allergy Pipeline Overview, House Dust Mite Allergy Pipeline, House Dust Mite Allergy Pipeline Assessment
Contents:
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy Overview
Therapeutics Development
An Overview of Pipeline Products for House Dust Mite Allergy
House Dust Mite Allergy Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
House Dust Mite Allergy Therapeutics – Products under Development by Companies
Companies Involved in House Dust Mite Allergy Therapeutics Development
ALK-Abello A/S
Stallergenes S.A.
Allergopharma Joachim Ganzer KG
Circassia Holdings Ltd.
ImVisioN Therapeutics AG
Genetic Immunity, LLC
Biomay AG
House Dust Mite Allergy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ToleroMune House Dust Mite T Cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitizax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACTAIR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acaroid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVN-Mite - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermAll Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite Peptide Carrier Fusion Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite RNA Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite Hypoallergenic Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite Allergy Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for House Dust Mite Allergy, H1 2012
Products under Development for House Dust Mite Allergy – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
ALK-Abello A/S, H1 2012
Stallergenes S.A., H1 2012
Allergopharma Joachim Ganzer KG, H1 2012
Circassia Holdings Ltd., H1 2012
ImVisioN Therapeutics AG, H1 2012
Genetic Immunity, LLC, H1 2012
Biomay AG, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
House Dust Mite Allergy Therapeutics – Drug Profile Updates
List of Figures
Number of Products under Development for House Dust Mite Allergy, H1 2012
Products under Development for House Dust Mite Allergy – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
House Dust Mite Allergy - Pipeline Review, H1 2012
Web Address
http://www.researchandmarkets.com/reports/2167189
Office Code
OC8DIQSSSPPOSV
Report Formats
Please enter the quantity of the report format you require.
Contact information
Please enter all the information below in block capitals.
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Expiry Date:

/
Issue date:

/
(Diners Club only)

Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)